Sign In
Buy IRWD
$4.23
+0.500 (+13.40%)
At Close: Jul 31, 2026
Buy The Dip: 2 Top Undervalued Stocks Averaging 394% Forward EPS Growth
09:00am, Friday, 31'st Jul 2026
Despite the recent market selloff, earnings expectations continue to rise: The S&P 500's Q2 EPS is projected to grow by 37.9%, while net profit margins could reach a 15-year high. Buying the dip can p
Ironwood Pharmaceuticals: One Trial Stands Between Bargain And Bust
09:43am, Thursday, 30'th Jul 2026
Ironwood Pharmaceuticals trades at a 40% discount to its risk-adjusted sum-of-the-parts valuation, anchored by LINZESS and apraglutide. I assign a 'Buy' rating on IRWD and a $6.3 price target, citing
Here's Why Ironwood Pharmaceuticals (IRWD) is a Strong Momentum Stock
10:52am, Wednesday, 15'th Jul 2026
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life‑changing therapies for people living with gastrointestinal (GI) an
4 Defensive Stocks to Take Refuge in as Tech Sell-off Continues
09:26am, Wednesday, 08'th Jul 2026
COLL, IRWD, AMTB and DUK stand out as defensive stock picks as investors rotate from AI-driven tech amid the ongoing sell-off and seek safer sectors.
Zacks Industry Outlook Indivior, Aurinia, Ironwood, Altimmune and Marker
06:01am, Friday, 26'th Jun 2026
Indivior, Aurinia, Ironwood, Altimmune and Marker have been highlighted in this Industry Outlook article.
5 Small Drug Stocks to Invest in Amid a Biotech Comeback
09:41am, Thursday, 25'th Jun 2026
Innovation is at its peak in the Zacks Medical-Drugs industry. INDV, AUPH, IRWD, ALT and MRKR may prove to be good additions to one's portfolio.
Can Linzess Continue Driving IRWD's Revenue Growth Through 2026?
10:40am, Thursday, 11'th Jun 2026
Ironwood sees Linzess momentum as strong demand, a pediatric expansion and pricing changes are expected to boost revenues and profit in 2026.
Ironwood Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference
04:05pm, Thursday, 28'th May 2026
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), today announced that management will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, J
IRWD's Linzess Wins FDA Nod for Expanded Pediatric Constipation Use
11:10am, Thursday, 28'th May 2026
Ironwood gains FDA approval to expand Linzess use to children aged two to five years with functional constipation.
FDA Approves Use of LINZESS® (linaclotide) in Pediatric Patients Two Years of Age and Older with Functional Constipation (FC)
10:01am, Wednesday, 27'th May 2026
[url="]Ironwood Pharmaceuticals, Inc.[/url] (Nasdaq: IRWD), a biotechnology company developing and commercializing life changing therapies for people living wi
FDA Approves Use of LINZESS® (linaclotide) in Pediatric Patients Two Years of Age and Older with Functional Constipation (FC)
10:00am, Wednesday, 27'th May 2026
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life changing therapies for people living with gastrointestinal (GI) and
Ironwood Pharmaceuticals: A Contrarian Buy Opportunity
08:17pm, Thursday, 21'st May 2026
Ironwood Pharmaceuticals presents a contrarian buy opportunity after a 14.5% decline driven by CFO resignation and insider selling. At the current $3.49 quote, IRWD fundamentals remain intact, support
Ironwood Pharmaceuticals: CFO Resignation Knocks Shares - A Downgrade Is Due
04:08pm, Wednesday, 13'th May 2026
Ironwood Pharmaceuticals is downgraded to Hold after the CFO's resignation and despite record Q1 2026 Linzess-driven revenues. IRWD guides for $1.125–$1.175bn in Linzess sales and $450–$475m in to
Ironwood Pharmaceuticals Q1 Earnings Call Highlights
04:14pm, Friday, 08'th May 2026
Ironwood Pharmaceuticals NASDAQ: IRWD reported a strong start to 2026 and reiterated its full-year outlook, pointing to sharp first-quarter growth for LINZESS and continued progress toward a confirmat
